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Abstract
Objectives—To examine the relationship between N-terminal pro-brain natriuretic peptide (NT-
proBNP) and exercise capacity in a large contemporary cohort of patients with chronic heart
failure.
Background—Natriuretic peptides such as NT-proBNP are important biomarkers in heart
failure. The relationship between NT-proBNP and exercise capacity has not been well studied.
Methods—We analyzed the relationship between baseline NT-proBNP and peak VO2 or distance
in the 6 minute walk test in 1383 subjects enrolled in the HF-ACTION study. Linear regression
models were used to analyze the relationship between NT-proBNP and peak VO2 or distance in
the 6 minute walk test in the context of other clinical variables. Receiver operator curve (ROC)
analysis was used to evaluate the ability of NT-proBNP to accurately predict a peak VO2 < 12 mL/
kg/min.
Results—NT-proBNP was the most powerful predictor of peak VO2 (partial R2=0.13, p<0.0001)
out of 35 candidate variables. Although NT-proBNP was also a predictor of distance in the 6
minute walk test, this relationship was weaker than that for peak VO2 (partial R2 = 0.02,
p<0.0001). For both peak VO2 and distance in the 6 minute walk test, much of the variability in
exercise capacity remained unexplained by the variables tested. ROC analysis suggested NT-
proBNP had moderate ability to identify patients with peak VO2 < 12 mL/kg/min (c-index=0.69).
Conclusions—In this analysis of baseline data from HF-ACTION, NT-proBNP was the
strongest predictor of peak VO2 and a significant predictor of distance in the 6 minute walk test.
Despite these associations, NT-proBNP demonstrated only modest performance in identifying
patients with a low peak VO2 who might be considered for cardiac transplantation. These data
suggest that, while hemodynamic factors are important determinants of exercise capacity, much of
the variability in exercise performance in heart failure remains unexplained by traditional clinical
and demographic variables.
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Circulating biomarkers play an increasingly critical role in the diagnosis and management of
patients with chronic heart failure1. Natriuretic peptides such as brain natriuretic peptide
(BNP) and its N-terminal pro-brain natriuretic peptide (NT-proBNP) have been
demonstrated to be powerful tools for the diagnosis, risk stratification, and management of
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patients with heart failure2. In addition to being useful for clinical management, biomarkers
may suggest insights into the mechanisms underlying important physiologic relationships.
Exercise intolerance, typically manifest as exertional dyspnea, is the major morbidity of
chronic heart failure. Both maximal (as measured by peak oxygen uptake (peak VO2))3, 4
and sub-maximal (as measured by distance in the 6 minute walk test)5 exercise capacity
have been demonstrated to be of substantial prognostic importance in chronic heart failure.
Assessment of peak VO2 plays a central role in risk stratification of patients with advanced
heart failure being considered for cardiac transplantation6. Despite the clinical importance of
exercise capacity, substantial controversy persists about the primary determinants of
exercise intolerance in heart failure, and the relative contribution of cardiac performance,
hemodynamic factors, pulmonary function, and peripheral skeletal muscle remain
incompletely understood7–11. The purpose of this study was to evaluate the association of
NT-proBNP with peak VO2 and distance in the 6 minute walk test in a large cohort of
patients enrolled in a randomized trial of exercise training, the Heart Failure and a
Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.
Methods
Details of design, rationale, and primary results of HF-ACTION have been published
elsewhere12, 13. Briefly, HF-ACTION (clinicaltrials.gov, NCT00047437) was a randomized
clinical trial evaluating the effect of exercise training on long term morbidity and mortality
in patients with chronic heart failure due to left ventricular systolic dysfunction. Enrolled
patients were randomized to exercise training in addition to usual care versus usual care
alone. HF-ACTION was approved by local Institutional Review Boards, and all enrolled
patients provided written informed consent.
Exercise Testing
2329 of 2331 patients enrolled in the HF-ACTION study underwent baseline exercise
testing as has been previously described12, 14. Patients underwent symptom limited
cardiopulmonary exercise testing with gas exchange analysis to evaluate peak VO2, utilizing
either a motor driven treadmill or exercise cycle ergometer protocol. For treadmill exercise,
a modified extended Naughton protocol was used; for cycle ergometer exercise, a ramped
protocol was used with 10 watt/minute increases starting at 0 watts. A six minute walk test
was to be performed as previously described5 at least 2 hours before or after baseline
cardiopulmonary exercise (CPX) testing. CPX testing data were interpreted by a central core
laboratory (Duke University).
NT- proBNP Assay
Patients enrolled in the HF-ACTION study and in the biomarker substudy underwent plasma
collection at the baseline, 3-month, and 12-month visits. Baseline blood samples were
obtained on the same day as baseline exercise testing, but were to be obtained prior to
exercise. Samples were collected via peripheral vein into EDTA containing tubes, and then
centrifuged immediately and stored at −70° C for subsequent analysis. Assays for NT-
proBNP were performed using a commercially available assay platform (Roche Diagnostics,
Inc.) at a central core laboratory (Duke University).
Statistical Analysis
Continuous variables were presented as medians with the 25th and 75th percentiles.
Categorical data were presented as percentages. Patient characteristics were compared
between patients above and below the median value of Peak VO2 using the Chi square test
for categorical, and the t-test for continuous variables. Where specific distributional
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assumptions for these tests are were violated, the Fisher's Exact and Wilcoxon signed rank
tests, respectively, were used instead. Because data on NT-proBNP were not normally
distributed, we log transformed NT-proBNP values (ln[NT-proBNP]) for all statistical
analyses.
The aim of this analysis was to evaluate the relationship between NT proBNP and measures
of exercise capacity, specifically the ability of NT-proBNP to predict peak VO2 and distance
in the 6 minute walk test alone and in combination with other clinical predictors. We used
Pearson correlation coefficients to assess the univariable relationship between NT-proBNP
and each of these primary endpoints, as well as other exercise parameters of interest (CPX
test duration and Ve/VCO2 slope).
In order to understand the relationship between NT-proBNP and exercise capacity in the
context of other clinical variables, we created multivariable linear regression models for
both peak VO2 and distance in the 6 minute walk test, with the measure of exercise capacity
as the dependent outcome variable. For each of these endpoints, the best predictive model
was constructed using baseline clinical data from the overall trial population (n=2331) in a
backwards variable selection process. Variables were sequentially eliminated from an initial
set of candidate predictors, the variable with the highest P-value eliminated at each step.
This stage ended when all remaining variables had a P-value < 0.05. In order to further
isolate factors most significant in determining functional capacity measures, all variables
which remained in the model derived by this process, but which possessed a partial R2 <0.01
after eliminating non-significant predictors, were also removed. Candidate variables
considered for each model were 35 demographic and clinical variables thought to be
potential predictors of exercise capacity based on review of the literature and clinical
judgment (see Appendix for list of candidate variables). Once a best model was generated
from the overall study population, this model was then applied to the subset of patients
(n=1383) for whom NT-proBNP data were available. Finally, NT-proBNP was added to the
model to evaluate the relative contribution of NT-proBNP in the context of other predictors
of exercise capacity. We also evaluated interaction terms for NT-proBNP with age, gender,
and body mass index based on previous data showing that these were important potential
determinants of both NT-proBNP levels and exercise capacity. The relative strength of
association between each predictor variable and exercise capacity was based on the partial
R2 in the final multivariable model. A p value <0.05 was considered statistically significant
for all analyses.
Because peak VO2 ≤ 12 mL/kg/min has been recommended as a clinically important cut
point for cardiac transplant listing in patients treated with beta-blocker therapy6, we used
receiver-operator curve (ROC) analysis to assess the ability of NT-proBNP to predict a peak
VO2 ≤ 12 mL/kg/min in the study population. The area under the curve for the ROC was
used to assess the accuracy of NT-proBNP levels in predicting a peak VO2 ≤ 12 mL/kg/min.
Results
Study Cohort
Baseline characteristics for the study cohort are shown in Table 1. Generally, the cohort in
whom NT-proBNP data were available (n=1383) was similar to the overall study population
(n=2331). The study cohort was diverse with regard to gender (29% women), race (34%
African-American), and age (20% with age ≥ 70). The mean ejection fraction was 25% and
most patients (66%) had NYHA class II heart failure symptoms. Notably, patients enrolled
in HF-ACTION were exceptionally well-treated in terms of evidence-based therapies, with
extremely high rates of utilization for beta-blockers (95%), angiotensin-converting enzyme
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(ACE) inhibitors or angiotensin II receptor blockers (ARBs) (95%), and implantable
cardioverter-defibrillators (ICDs) (39%).
Exercise Capacity and NT-proBNP
The median peak VO2 in the study cohort was 14.4 mL/kg/min (inter-quartile range 11.5 –
17.5 mL/kg/min), consistent with moderate impairment of exercise capacity. The median
distance in the 6 minute walk test was 372 meters (interquartile range 300 – 431 meters).
The median NT-proBNP was 815 pg/mL (interquartile range 341 – 1805 pg/mL). In
univariable analysis, there was a significant correlation between the logarithm of NT-
proBNP and all measures of exercise capacity: peak VO2 (r = −0.38, p<0.0001), distance in
the 6 minute walk test (r = −0.23, p<0.0001), CPX duration (r = - 0.35, p<0.0001), and Ve/
VCO2 slope (r=0.50, p<0.0001). Scatter plots for each of the relationships are shown in
Figure 1.
NT-proBNP in the Context of Other Predictors: Multivariable Modeling
In order to understand the relationship between exercise capacity and NT-proBNP in the
context of other demographic and clinical variables, we evaluated the added value of NT-
proBNP in the context of those clinical variables most predictive of exercise capacity in the
overall HF-ACTION cohort. In the HF-ACTION study as a whole, the most significant
predictors of peak VO2 were age, race, body mass index, NYHA class, and gender. When
NT-proBNP was entered into the multivariable model for peak VO2, ln(NT-proBNP) was
strongly associated with peak VO2 even after adjustment for other determinants (p<0.0001,
partial R2 = 0.13). In the final model that included ln(NT-proBNP), ln(NT-proBNP) was the
strongest overall predictor of peak VO2 (partial R2 = 0.13), followed by body mass index
(partial R2 =0.13) and age (partial R2 = 0.09). The addition of NT-proBNP to the best
clinical model raised the R2 for the overall model from 0.38 (clinical model only) to 0.46
(clinical model + NT-proBNP). The final multivariable regression model for predicting peak
VO2 is shown in Table 2.
Using the same approach, we investigated the added value of NT-proBNP in predicting
distance in the 6 minute walk test. The strongest clinical predictors for distance in the 6
minute walk test were age, NYHA class, height, weight, race, and the presence of peripheral
vascular disease. As for peak VO2, the NT-proBNP remained a highly significant predictor
of distance in the 6 minute walk test (p=<0.0001) even after adjustment for other clinical
predictors. Unlike peak VO2, however, the relative contribution of NT-proBNP to prediction
of distance in the 6 minute walk test was modest (partial R2 = 0.020). NT-proBNP was the
5th strongest overall predictor of performance in the 6 minute walk test, after NYHA class,
age, height, and weight (Table 3). The addition of NT-proBNP to the best clinical model
resulted in a modest improvement in overall model performance (R2 changed from 0.28 to
0.30).
Impact of Age, Gender, and Body Mass Index
Because age, gender, and body mass index may affect both NT-proBNP levels and exercise
capacity, we explored the possibility of differential relationship between NT-proBNP and
peak VO2 and distance in the 6 minute walk test for each of these variables using interaction
terms in the overall models. For each of gender and obesity (defined as body mass index >
30 kg/m2), we found evidence for a quantitative interaction between NT-proBNP and peak
VO2. There was a stronger correlation between NT-proBNP and peak VO2 in men compared
to women (R = - 0.44 for men vs. −0.33 for women, p <0.0001 for interaction) and in non-
obese patients compared to obese patients (R = - 0.48 for BMI ≤ 30 vs. −0.36 for BMI < 30,
p = 0.04 for interaction). There was also evidence for a quantitative interaction between age
and the correlation of NT-proBNP and distance in the 6 minute walk test, with older patients
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(above the median age of 58.5 years) having a stronger correlation between NTproBNP and
distance in the 6 minute walk test than younger patients (R = −0.24 for age > median vs.
−0.13 for age < median, p < 0.001 for interaction).
NT-proBNP as a Surrogate for Peak VO2
Since assessment of peak VO2 is central to the selection of patients for cardiac
transplantation, we examined the sensitivity and specificity of NT-proBNP levels for
predicting peak VO2 < 12 mL/kg/min. This cut-point was chosen based on recent guidelines
for transplant evaluation in patients treated with beta-blockers (95% of patients in HF-
ACTION were taking beta-blockers at enrollment)6. Three hundred ninety three patients
(29%) in the study cohort had peak VO2 < 12 mL/kg/min. The optimal NT-proBNP cut-off
for predicting a peak V02 < 12 mL/kg/min was 876 pg/mL, which had a sensitivity of 0.67,
a specificity of 0.61, positive predictive value of 0.63, and negative predictive value of 0.65.
The area under the curve for the ROC curve was 0.69, suggesting modest discriminatory
ability for NT-proBNP in predicting a low peak VO2 (Figure 2)
Discussion
The primary finding of this analysis was that NT-proBNP levels were associated with both
peak VO2 and distance in the 6 minute walk test in a large well-treated contemporary cohort
of patients with chronic heart failure. NT-proBNP was the most significant overall predictor
of peak VO2 even after adjustment for 35 demographic and clinical candidate variables. For
distance in the 6 minute walk test, NT-proBNP was also a significant independent predictor
of exercise capacity, although the relationship was weaker than that for peak VO2. These
data represent the largest analysis to date evaluating the relationship between natriuretic
peptide levels and exercise capacity in heart failure.
Previous data on the relationship between exercise capacity and natriuretic peptide levels are
primarily from small single center studies of patients referred for exercise testing. Smaller
studies by Kruger et al, Kallistratos et al, and Passino et al have demonstrated significant
correlations (r= −0.56, −0.77, and −0.53 respectively) between natriuretic peptide levels and
peak VO2 in patients with heart failure referred for exercise testing15–18. Similarly, other
studies have found higher BNP or NT-proBNP levels to be associated with shorter distance
in the 6 minute walk test19, 20. Our findings regarding the relationship between NT-proBNP
and exercise capacity are broadly consistent with these prior results, but extend them in
several important areas. First, the detailed ascertainment of baseline characteristics, large
sample size, and broadly representative study cohort of the HF-ACTION study allowed us to
perform detailed adjustment for other demographic and clinical characteristics that might
impact exercise capacity. Additionally, the size of our cohort also allowed us to evaluate the
relationship in relevant subgroups. We found the relationship between peak VO2 and NT-
proBNP was stronger for men and for non-obese patients, potentially due to the known
effects of gender and obesity on NT-proBNP levels21, 22. Finally, ours is the first study to
examine the differences between peak VO2 and distance in the 6 minute walk test in relation
to the NT-proBNP levels in the same patient population. The correlation between NT-
proBNP and exercise capacity, especially distance in the 6 minute walk test, seen in our
study was somewhat weaker in absolute terms than that seen in previous studies, possibly
due to variability introduced by a multi-center trial as compared to a single center study.
Although correlation coefficients and linear regression models are useful for quantifying
relationships between continuous variables, they are not readily applicable to individual
patients for clinical use. Notably, despite the strong association between NT-proBNP levels
and peak VO2 in multivariable models, the performance of NT-proBNP in predicting a peak
VO2< 12 mL/kg/min was modest, with a c-index of 0.69, a sensitivity of 0.67, and a
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specificity of 0.61 at an optimal NT-proBNP cut point of 876 pg/mL. These data suggest
that NT-proBNP is not a sufficient predictor of peak VO2 to act as a clinically useful
surrogate for identifying those patients with a low peak VO2 that might be considered for
transplant listing. Notably, of the exercise variables evaluated, NT-proBNP was most
strongly correlated with Ve/VCO2 slope, which has been suggested to be a more powerful
predictor of prognosis than peak VO2 in several studies23, 24. Previous data have shown that
natriuretic peptides and cardiopulmonary exercise testing provide independent and
complementary information in predicting prognosis in patients with heart failure.25
Mechanistic Considerations
The physiologic determinants of exercise capacity in heart failure have been the subject of
substantial interest. Measures of cardiac systolic function such as ejection fraction have not
been shown to correlate well with exercise capacity26. Although the relationship between
hemodynamic measures (such as cardiac output or ventricular filling pressures) and maximal
exercise capacity is stronger than that of ejection fraction, the invasive assessment of
hemodynamics and exercise is technically challenging and has been limited to small studies
of highly selected populations27, 28. A substantial component of exercise intolerance in heart
failure remains unexplained, and is posited to be due to non-cardiac factors such as changes
in peripheral skeletal muscle29. Although natriuretic peptide levels may reflect a variety of
cardiac processes including ischemia, inflammation, and oxidative stress, they primarily
reflect central hemodynamics30, and therefore serve as a non-invasive means to estimate the
relative contribution of hemodynamic factors to exercise capacity in heart failure. The
finding that NT-proBNP was the strongest overall predictor of peak VO2 out of 35 candidate
variables suggests that hemodynamic factors play a significant role in mediating exercise
performance in heart failure. Importantly, however, even with NT-proBNP included in the
best clinical model, the overall model performance (R2 = 0.46) suggest that over half of the
variability in exercise capacity among patients with heart failure is not explained by the
factors analyzed in our models. This finding argues for the importance of other unmeasured
variables (such as skeletal muscle abnormalities or genetic factors) as important
determinants of exercise capacity in heart failure, and suggests the need for ongoing
research into the mechanisms of exercise intolerance in these patients.
Maximal vs. Sub-maximal Capacity
Although NT-proBNP was also a significant predictor of distance in the 6 minute walk test,
this relationship was substantially less strong than that seen for peak VO2. Previous data
suggest that distance in the 6 minute walk test may be more influenced by non-physiologic
factors (such as patient motivation and investigator prompting) than is peak VO2.31 In
comparing the best clinical models with NT-proBNP for peak VO2 and distance in the 6
minute walk test, there was substantially more variability in distance in the 6 minute walk
test that was not explained by our models, suggesting that unmeasured factors and possibly
non-physiologic aspects may play a greater role in determining sub-maximal as compared to
maximal exercise capacity.
Limitations
As with any cross-sectional analysis, our study was able to demonstrate associations but is
unable to establish causation. The study population was from a multi-center randomized
trial, and patients enrolled in clinical trials are known to differ from the broader heart failure
population in potentially important ways32. As in previous large heart failure trials, the
population enrolled in HF-ACTION was somewhat younger and had a greater proportion of
non-ischemic heart failure etiology than the general heart failure population. Specific
strengths of this analysis include the use of a large, multi-center cohort with careful
phenotyping of baseline characteristics, extremely high utilization of contemporary evidence
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based therapy, and the use of centralized core laboratories to standardize analysis of both
exercise data and biomarker assays.
CONCLUSIONS
NT-proBNP was strongly associated with peak VO2 in a large well-treated cohort of patients
with heart failure due to left ventricular systolic dysfunction. NT-proBNP was the strongest
predictor of peak VO2, even after adjustment for multiple other demographic and clinical
characteristics. NT-proBNP was also significantly associated with distance in the 6 minute
walk test, although this relationship was substantially weaker than for peak VO2. These data
support the concept that hemodynamic factors play an important role in determining
exercise tolerance in heart failure, but also confirm that much of the variability in exercise
capacity in heart failure remains unaccounted for by currently available clinical measures.
Given that exertional limitation is the primary morbidity of heart failure, these findings
highlight the need for ongoing research in the determinants of exercise capacity in patients
with heart failure. Future analyses of data from the HF-ACTION trial will provide further
insights into the relationships between changes in circulating biomarkers, exercise training,
changes in exercise performance measures, and clinical outcomes over time.
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APPENDIX
Candidate Variables for Linear Regression Models for Predicting Peak V02 and distance in
the 6 minute walk test
• sex
• diabetes (history of)
• stroke (history of)
• hypertension (history of)
• prior CABG
• prior valve surgery
• prior percutaneous coronary intervention
• prior myocardial infarction
• peripheral vascular disease (history of)
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• chronic obstructive pulmonary disease (history of)
• depression (history of)
• atrial fibrillation/atrial flutter (history of)
• pacemaker
• bi-ventricular pacemaker
• on an ACE inhibitor at baseline
• on a beta blocker at baseline
• etiology of heart failure
• CPX mode (treadmill or bicycle)
• heart failure hospitalizations in the last 6 months (0, 1, 2, or 3+)
• region (4 regions of US, Canada, or France)
• race (Black or African American, White, or Other)
• NYHA class (II vs. III/IV) at baseline
• CCS angina class at baseline
• rest ECG ventricular conduction prior to baseline CPX test (normal, LBBB, RBBB,
IVCD, or paced)
• rest ECG rhythm prior to baseline CPX test (sinus, atrial fibrillation, or other)






• resting HR (clinic visit)
• resting HR (CPX test)
• LVEF
• age
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Association between ln (NT-proBNP) and Measures of Exercise Capacity; A. peak V02, B.
distance in the 6 minute walk test, C. CPX duration, and D. Ve/VCO2 slope.
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Receiver operator curve for NT-proBNP predicting peak V02 < 12 mL/kg/min. Optimal cut
point for maximizing performance was NTproBNP of 876 (sensitivity = 0.67, specificity =
0.61).
Felker et al. Page 13



















































































































































































































































































































































































































































































































































































































































































































































































































































































Felker et al. Page 16
Table 2





ln NT-proBNP -1.15 <0.0001 0.129
BMI −0.02 <0.0001 0.125
Age −0.10 <0.0001 0.086
Sex −2.17 <0.0001 0.075
Race -- <0.0001 0.058
NYHA class
  (II vs. III/IV)
−1.61 <0.0001 0.048
CPX mode 2.35 <0.0001 0.029




Diabetes mellitus −0.64 0.0020 0.007
Region -- 0.0017 0.002
LVEF 0.02 0.15 0.0016
Reference categories: sex = male, NYHA Class = Class II, CPX mode = bicycle
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Table 3






  (II vs. III/IV)
−59.19 <0.0001 0.091
Age −2.41 <0.0001 0.086
Height −2.41 <0.0001 0.057
Weight −1.10 <0.0001 0.056
ln NT-proBNP -10.49 <0.0001 0.020
Race -- <0.0001 0.019
Heart Failure hospitalizations -- <0.0001 0.018
PVD −35.95 0.0002 0.010
Region -- 0.0233 0.009
Reference categories: NYHA Class = Class II
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